Conference being held Oct. 11th to 13th, 2022 in Carlsbad, California
MONTRÉAL, September 20, 2022 – ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today that Co-CEO and COO David Millette will present in person at the annual Cell & Gene Meeting on the Mesa Conference to be held on October 11-13, 2022 in Carlsbad, California.
The presentation will provide an overview of the company, including its:
- UM171 cell expansion and rejuvenation commercial platform;
- ECT-001 expanded stem cell therapy late-stage clinical program for the treatment of severe blood disorders; and
- Cell & gene therapy pre-clinical pipeline.
|Event:||ExCellThera Corporate Presentation|
|Date:||Tuesday, October 11, 2022|
|Time:||11:00 AM Pacific Time|
|Location:||Oxford Biomedica Ballroom, Park Hyatt Aviara Resort, Carlsbad, CA|
Organized by the Alliance for Regenerative Medicine, the Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This year’s meeting is expected to attract over 1,700 attendees and enables key partnerships through more than 3,000 one-on-one meetings. Please visit www.meetingonthemesa.com for detailed conference information and registration.
UM171 is a proprietary molecule that leads to specific epigenetic modifications which have a profound impact on hematopoietic stem cell (HSC) self-renewal. UM171 has been cited in several scientific publications and has become the standard for HSC expansion in Cell & Gene Therapy. ExCellThera has developed commercial GMP grade UM171 which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA. With UM171’s broad range of use, ExCellThera is partnering with select partners for the use under license of UM171 to enhance Cell & Gene Therapy protocols by expanding HSCs and protecting them against process exhaustion and damage.
ECT-001 cell therapy combines proprietary molecule UM171, and an optimized culture system. ECT‑001 has been evaluated in nearly 100 adult and pediatric patients with severe blood disorders in several clinical trials in the United States and Canada (with additional clinical trials in Europe expected soon). ECT-001 cell therapy has received orphan drug designation and regenerative medicine advanced therapy (RMAT) designation from the FDA as well as orphan medicinal product designation, advanced therapy medicinal product (ATMP) classification and priority medicines (PRIME) designation from the EMA.
ExCellThera is a world leader in blood stem cell expansion and rejuvenation.
ExCellThera’s lead proprietary molecule, UM171, has become the standard for hematopoietic stem cell (HSC) expansion in Cell & Gene Therapy. UM171’s first-in-class mechanism of action has been shown to expand and rejuvenate HSCs, and to counteract exhaustion from culture and gene modification which represent important limitations in cell & gene therapies. ExCellThera has developed commercial GMP grade UM171 which can be integrated into the manufacturing process of various cell and gene therapy products as a reagent and is supported by a Type II Drug Master File (DMF) filed with the FDA.
In addition to ECT-001 cell therapy, ExCellThera also has a pre-clinical pipeline of next generation cell & gene therapies in adjacent fields of use.